The P2RY14 antibody is designed to target the P2Y14 receptor, a G protein-coupled receptor (GPCR) belonging to the purinergic receptor family. P2Y14 is activated by extracellular UDP-glucose and related nucleotide sugars, distinguishing it from other P2Y receptors that primarily bind nucleotides like ATP or ADP. This receptor plays a role in modulating immune responses, inflammation, and metabolic processes, with expression observed in immune cells (e.g., mast cells, dendritic cells), the nervous system, and certain epithelial tissues. Research highlights its involvement in diseases such as asthma, diabetes, and cancer, where it may regulate cell migration, cytokine release, or tumor progression.
P2RY14 antibodies are critical tools for detecting receptor expression, localization, and functional studies. They enable applications like Western blotting, immunohistochemistry, and flow cytometry to explore P2Y14's physiological and pathological roles. Challenges include low receptor abundance in tissues and potential cross-reactivity with other proteins, necessitating rigorous validation. Recent studies also investigate P2Y14 as a therapeutic target, driving interest in developing agonists/antagonists. However, its signaling mechanisms and disease-specific contributions remain incompletely understood, underscoring the need for high-quality antibodies to advance research in immunology, oncology, and drug discovery.